NASDAQ:MGNX MacroGenics (MGNX) Stock Price, News & Analysis $1.69 +0.25 (+17.36%) Closing price 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.65%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About MacroGenics Stock (NASDAQ:MGNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MacroGenics alerts:Sign Up Key Stats Today's Range$1.51▼$1.7050-Day Range$1.19▼$1.8152-Week Range$0.99▼$5.10Volume1.50 million shsAverage Volume909,741 shsMarket Capitalization$106.82 millionP/E RatioN/ADividend YieldN/APrice Target$3.60Consensus RatingModerate Buy Company Overview MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Read More MacroGenics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreMGNX MarketRank™: MacroGenics scored higher than 88% of companies evaluated by MarketBeat, and ranked 135th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMacroGenics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMacroGenics has only been the subject of 1 research reports in the past 90 days.Read more about MacroGenics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MacroGenics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.97% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MacroGenics has recently decreased by 0.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.61 Percentage of Shares Shorted6.97% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MacroGenics has recently decreased by 0.98%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment0.25 News SentimentMacroGenics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for MacroGenics this week, compared to 4 articles on an average week.Search Interest4 people have searched for MGNX on MarketBeat in the last 30 days. MarketBeat Follows10 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $150,515.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MacroGenics' insider trading history. Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Stock News HeadlinesMacroGenics (NASDAQ:MGNX) Director William Heiden Acquires 49,500 SharesAugust 22 at 9:11 AM | insidertrades.comMacroGenics, Inc. (NASDAQ:MGNX) Receives $3.60 Consensus PT from AnalystsAugust 21 at 2:17 AM | americanbankingnews.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.August 22 at 2:00 AM | Paradigm Press (Ad)MacroGenics (NASDAQ:MGNX) Given New $5.00 Price Target at Leerink PartnersAugust 18, 2025 | americanbankingnews.comComparing MacroGenics (NASDAQ:MGNX) & Prestige Consumer Healthcare (NYSE:PBH)August 18, 2025 | americanbankingnews.comCitizens JMP Keeps Their Hold Rating on MacroGenics (MGNX)August 17, 2025 | theglobeandmail.comMacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic PrioritiesAugust 16, 2025 | uk.finance.yahoo.comMacroGenics Revenue Doubles in Q2August 16, 2025 | theglobeandmail.comSee More Headlines MGNX Stock Analysis - Frequently Asked Questions How have MGNX shares performed this year? MacroGenics' stock was trading at $3.25 on January 1st, 2025. Since then, MGNX shares have decreased by 50.9% and is now trading at $1.5950. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) posted its quarterly earnings results on Thursday, August, 14th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.02. The biopharmaceutical company earned $22.24 million during the quarter, compared to analyst estimates of $28.06 million. MacroGenics had a negative net margin of 21.99% and a negative trailing twelve-month return on equity of 40.24%. Who are MacroGenics' major shareholders? MacroGenics' top institutional investors include Bellevue Group AG (15.72%), Armistice Capital LLC (9.45%), Acadian Asset Management LLC (3.95%) and EcoR1 Capital LLC (2.54%). Insiders that own company stock include Target N V Biotech, William K Heiden, Ezio Bonvini, Edward Hurwitz and Jeffrey Stuart Peters. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL). Company Calendar Last Earnings8/14/2025Today8/22/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGNX CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees430Year Founded2000Price Target and Rating Average Price Target for MacroGenics$3.60 High Price Target$5.00 Low Price Target$2.00 Potential Upside/Downside+128.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.97 million Net Margins-21.99% Pretax Margin-21.36% Return on Equity-40.24% Return on Assets-14.62% Debt Debt-to-Equity RatioN/A Current Ratio5.26 Quick Ratio3.11 Sales & Book Value Annual Sales$149.96 million Price / Sales0.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book2.13Miscellaneous Outstanding Shares63,210,000Free Float54,989,000Market Cap$99.56 million OptionableOptionable Beta1.65 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:MGNX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.